FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

asilington, D.C. 20549		

UIVIB APPROVAL								
	OMB Number:	3235-02						

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

de Carbonnel Francois	2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 09/08/2011						Officer below)	(give title		Other (s below)	pecify		
Street) THOUSAND OAKS CA 91320-1799	4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
Date	Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			Beneficia Owned Fo	s For ally (D) ollowing (I) (Form: (D) or	rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
					Amo	unt	(A) or (D)	Price	Reported Transacti (Instr. 3 a	ion(s)		1	Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
	ransaction ode (Instr.	Derivative Exp		Expiration Date of S (Month/Day/Year) Und Det (Institute of S		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Co	ode V	(A)		Date Exercisable	Expirati Date		Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Dividend (1) 09/08/2011 cquivalent	A	10.0336		(1)	(1)		Common Stock	10.0336	\$0	10.033	36	D	

1. The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount.

> /s/ Andrea A. Robinson, Attorney-in-Fact for Mr. de

Carbonnel

** Signature of Reporting Person

Date

09/12/2011

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.